NCT03959397 is a Phase 2 clinical trial of nab-paclitaxel in Breast Cancer Stage, sponsored by Jilin University.

Who is sponsoring NCT03959397?

NCT03959397 is sponsored by Jilin University.

What drugs are being tested in NCT03959397?

Interventions in NCT03959397: nab-paclitaxel.

What condition does NCT03959397 study?

NCT03959397 studies Breast Cancer Stage.

Is NCT03959397 still recruiting?

NCT03959397 is currently status unknown. Last updated 22 May 2019.

Last reviewed 2019-05-22 · How we verify

NCT03959397

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Paclitaxel Injection (Albumin-bound) for Neoadjuvant Treatment of Breast Cancer

Status unknown Phase 2 Last updated 22 May 2019

What this trial tests

Phase 2 trial testing nab-paclitaxel in Breast Cancer Stage in 250 participants. Status unknown.

Timeline

1 June 2019

Primary endpoint
1 June 2021

1 December 2024

Quick facts

Lead sponsor	Jilin University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	250
Start date	1 June 2019
Primary completion	1 June 2021
Estimated completion	1 December 2024
Sites	1 location across China

Drugs / interventions tested

nab-paclitaxel (nab-paclitaxel) — full drug profile →

Conditions studied

Breast Cancer Stage — all drugs for Breast Cancer Stage →

Sponsor

Jilin University

Who can join

18 and older, any sex, with Breast Cancer Stage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Neoadjuvant chemotherapy is a systemic cytotoxic drug therapy for non-metastatic tumors before local therapy, Now it has become an important part of standard treatment for a stage II, III, and the first clinical Ⅳ breast cancer .Both domestic and foreign authoritative guidelines recommend the use of albumin-binding paclitaxel in the neoadjuvant treatment of breast cancer .In addition, clinical studies at home and abroad have preliminarily confirmed the application value and therapeutic benefit of albumin-binding paclitaxel in breast cancer neoadjuvant therapy, and the toxic and side effects can be tolerated.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting Autophagy with Natural Products as a Potential Therapeutic Approach for Cancer.
Al-Bari MAA, Ito Y, Ahmed S, Radwan N, et al · · 2021 · cited 34× · PMID 34575981 · DOI 10.3390/ijms22189807
Breast cancer tumor microenvironment affects Treg/IL-17-producing Treg/Th17 cell axis: Molecular and therapeutic perspectives.
Seif F, Torki Z, Zalpoor H, Habibi M, et al · · 2023 · cited 31× · PMID 36816749 · DOI 10.1016/j.omto.2023.01.001

Verify or expand the search:

Other trials of nab-paclitaxel

Trials testing the same drug.

NCT07018063 — Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer · Phase 2 · not yet recruiting
NCT05562297 — Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer · Phase 2 · not yet recruiting
NCT06528093 — A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Ta · Phase 1 · terminated
NCT06445062 — Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors · Phase 1, PHASE2 · recruiting
NCT06390059 — EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-Li · Phase 2 · active not recruiting

Other recruiting trials for Breast Cancer Stage

Currently open trials in the same condition.

NCT06234488 — Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study · active not recruiting
NCT05142800 — Screening For BCRL In Targeted Therapy For Breast Cancer · active not recruiting

Other Jilin University trials

Trials by the same sponsor.

NCT07253948 — Distribution Characteristics of Helicobacter Pylori · recruiting
NCT06454461 — Efficacy of Upadacitinib After NECS in Vitiligo · NA · recruiting
NCT06397066 — White Light Endoscopy and Magnifying Endoscopy in Assessing the Status of Hp Infection · recruiting
NCT06079554 — Microbiota and Metabolomics of Intestinal Type of Gastric Cancer · recruiting
NCT06076369 — Differentiation of Tubular Adenoma and Colonic Innominate Groove Under EC Endoscopy · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03959397 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jilin University
Last refreshed: 22 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03959397.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing